LH reports Q1 2026 results on May 21 with a notable divergence between analyst conviction and insider behaviour defining the pre-earnings setup.
The insider activity is the clearest tension heading into the print. CEO Adam Schechter sold nearly $7 million of stock on March 26, followed by a further $1.5 million sale on May 11 — just ten days before the release. He was not alone: the CFO equivalent, the Chief Medical Officer, Chief Legal Officer, and Chief Marketing Officer all sold on the same day in late March. The 90-day insider net position runs to roughly $15 million in net proceeds, with no disclosed purchases to offset the flow. That pattern signals a c-suite broadly comfortable locking in gains ahead of a scheduled catalyst.
Analyst sentiment runs in the other direction. The consensus is constructive, with seven analysts holding Outperform or equivalent ratings against four on Hold, and JP Morgan carrying a $330 price target — implying roughly 24% upside from the current $250.40 close. Evercore ISI raised its target to $300 in early April while maintaining Outperform, confirming the bullish thesis still has recent support. Bulls point to a 10% year-on-year backlog improvement to $8.71 billion, a net book-to-bill of 1.11x, and 8.9% revenue growth in the Diagnostic segment. Bears counter with reimbursement risk under PAMA, integration challenges from acquisitions, and modest volume growth that fell short of consensus — total requisitions grew 4.9% against a 5.2% estimate.
Short positioning tells a calmer story. SI is running at 3.9% of free float — meaningful but not extreme — and has been largely flat over the past month, moving less than 1% over 30 days. Borrow conditions are relaxed: cost to borrow is near 0.43%, down about 14% over the past month, and the short score of 40.8 ranks in the lower half of the ORTEX universe. Options, meanwhile, have shifted notably less defensive. The put/call ratio has dropped to 1.10 — well below its 20-day average of 1.83 and roughly 1.3 standard deviations below the mean. That represents one of the more bullish options reads of the past year for this name, suggesting traders have been rotating out of downside protection in recent sessions.
The stock is down 6.9% over the past month and trades at a trailing P/E near 13.5x and EV/EBITDA of 10.2x — undemanding multiples for a business growing revenue in the high single digits. The RSI sits at 35, touching technically oversold territory, which adds a recovery angle for bulls. The May 21 print will ultimately test whether the revenue and volume trajectory justifies a re-rating from these compressed multiples — or whether the c-suite's decision to sell into strength was well-timed.
See the live data behind this article on ORTEX.
Open LH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
